RVNC News and Press, Revance Therapeutics Inc.

2024-06-20 16:40:55 ET Summary Revance Therapeutics, Inc. operates in the aesthetics and therapeutics markets, selling Daxxify and RHA Collection of dermal fillers in the U.S. Despite positive guidance for 2024, the Revance stock price has fallen by nearly 70% year-to-date, facing...

2024-05-10 12:57:54 ET Gainers: Novavax NVAX +106% . AEye LIDR +67% . ITeos Therapeutics ITOS +48% . Sensus Healthcare SRTS +35% . Inseego Corp INSG +32% . Sweetgreen SG +33% . Organogenesis Holdings ORGO +33% . Caredx CDNA +32...

2024-05-09 22:42:09 ET Revance Therapeutics Inc. (RVNC) Q1 2024 Results Earnings Conference Call May 9, 2024, 04:30 PM ET Company Participants Laurence Watts - Investor Relations, New Street IR Mark Foley - Chief Executive Officer Tobin Schilke - Chief Financial ...

2024-05-09 16:50:00 ET More on Revance Therapeutics Revance Therapeutics Inc. (RVNC) Q4 2023 Earnings Call Transcript Revance: Stock Bouncing On Q4 Earnings, But Long-Term Challenges Remain Revance Therapeutics Q1 2024 Earnings Preview Survey finds GLP-1 user...

- Total net product revenue (DAXXIFY® and RHA® Collection) of $51.7 million, a YoY increase of 13%. - DAXXIFY® net revenue of $22.1 million, after a reduction of $2.0 million related to a consumer coupon program. - Toxin market share increased from 3.0% in Q4’23 to 3...

2024-05-08 17:35:55 ET Major earnings expected after the bell on Thursday include: Unity Software ( U ) Main Street Capital Corporation ( MAIN ) Marathon Digital Holdings ( MARA ) Wheaton Precious Metals Corp. ( WPM ) Blink Charging Co. ( BLNK ) ...

Conference Call Scheduled for Thursday, May 9, 2024 at 4:30 p.m. ET. Revance Therapeutics, Inc. (NASDAQ: RVNC), today announced that the company will release first quarter 2024 financial results on Thursday, May 9, 2024, after the close of market. Revance will host a corresponding confe...

2024-04-22 16:53:54 ET Gainers: Oportun Financial  ( OPRT ) +5% . Humacyte ( HUMA ) +2% . Revance Therapeutics ( RVNC ) +2% . Office Properties Income  ( OPI ) +2% . Axcelis Technologies ( ACLS ) +1% . Losers: C...

2024-04-16 10:47:43 ET More on AbbVie AbbVie: Great To Be Proven Wrong - Still Not A Buy AbbVie: Bulletproof Fundamentals AbbVie: Despite The Run, Shares Still Look Attractive, Yielding 3.67% AbbVie keeps Humira market share near 100% despite biosimilars: rep...

– Two presentations highlighting data on DAXXIFY® for the treatment of cervical dystonia, including a new analysis from ASPEN trials assessing patient-desired retreatment intervals and one abstract examining the influence of DAXXIFY’s formulation on clinical performance ...